Index

Note: Page numbers of article titles are in boldface type.

A

AASK (African American Study of Kidney Disease and Hypertension) trial, 666–667
Abacavir, for HIV infection prevention, 931, 940
Abatacept, 728
Abscesses, antimicrobial use guidelines for, 912–914
ABT-593, for hepatitis C, 827–834
Acamprosate, for alcohol use disorder, 897
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, 648, 666–667
Acebutolol, 677
Acenocoumarol. See Vitamin K antagonists.
Acetaminophen
  for musculoskeletal pain, 873
  for opioid use disorder, 905
  for osteoarthritis, 881
Action in Diabetes and Vascular Disease (ADVANCE), 648
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 648, 666–667
Acute illness, anticoagulants for, 702
Adalimumab, 728
Addiction. See Substance abuse disorders.
ADOPT trial, 702
ADVANCE (Action in Diabetes and Vascular Disease), 648
African American Study of Kidney Disease and Hypertension (AASK) trial, 666–667
Albiflutide, 654–655, 657–658
Alcohol use disorder, 896–900
Aldosterone antagonists, 671
Alendronate, for osteoporosis, 811–815
Alfuzosin, for benign prostatic hyperplasia, 801
Aliskiren, 673
Allergy. See Pulmonology and allergy.
ALLHAT (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial), 669
Allopurinol, 722–723
Alogliptin, 651–652
Alosteron, for irritable bowel syndrome, 835–837
Alpha-adrenergic agonists, for hypertension, 678
Alpha-adrenergic antagonists, for benign prostatic hyperplasia, 801
Alpha-adrenergic blockers, for hypertension, 678
6-Alpha-reductase inhibitors, for benign prostatic hyperplasia, 801–802
Alprostadil, 798–800
Amantadine
  for Parkinson’s disease, 738–739, 743
  for restless leg syndrome, 752–753
Amiloride, 671
Amiodarone, 945
Amlodipine, 674
Amoxicillin, 841–842
Angioedema, 858–859
Angiotensin receptor blockers, 673, 683
Angiotensin-converting enzyme inhibitors
  angioedema due to, 858–859
  for hypertension, 672, 683
Antacids, 840, 843, 944
Anticholinergic agents
  for asthma, 863–864
  for benign prostatic hyperplasia, 802
  for Parkinson’s disease, 739, 743
  for rhinitis, 853, 855
Anticoagulants, 695–718
  choice of, 703–705
  classes of, 695–696
  clinical applications of, 697–703
  direct, 710–712
  interactions with, 944
  parenteral, 712–714
  practical applications for, 703–705
  switching between, 703
  vitamin K antagonists. See Vitamin K antagonists.
Anticonvulsants, for neuropathic pain, 880
Antidepressants
  for back pain, 877–878
  for irritable bowel syndrome, 837
  for neuropathic pain, 879
  interactions with, 944–945
Antihistamines
  for rhinitis, 853–854
  for urticaria, 857
Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 669
Antihypertensives. See Hypertension, therapy for.
Antileukotriene agents, for rhinitis, 854, 856
Antimicrobial agents, 911–926
  new usage guidelines for, 912–915
  novel, 915–922
Antiretroviral therapy, for HIV infection prevention, 927–950
  drug side effects and interactions in, 939–946
  drugs used for, 929
  history of, 927–928
  in mother-to-child transmission, 934
  in postexposure prophylaxis, 934–937
  in pre-exposure prophylaxis, 937–939
  initiation of, 929–933
  monitoring of, 929–933
  timing of, 928–929
  treatment as, 928
Antispasmodics
for back pain, 875
   for irritable bowel syndrome, 835–837
Antispasticity medications, for back pain, 875–876
Antiviral agents, for hepatitis C, 827–834
Apomorphine, for Parkinson's disease, 737, 742
Apremilast, 727
Argatroban, 712–714
ASPECT trials, 919–921
Aspirin
   for diabetes type 2, 659
   for musculoskeletal pain, 871–872
Asthma, 859–865
Atazanavir, for HIV infection prevention, 931, 941–942, 944
Atenolol, 676, 746
Atorvastatin, for diabetes type 2, 659
Atrial fibrillation, stroke in, 697–698
Atropine, for drooling, 739, 744
Autoimmune conditions, therapy for, 719–731
Azathioprine, 727
Azilsartan, 673

B
Back pain, 874–877
Baclofen, 840–841
   for alcohol use disorder, 899
   for back pain, 875–876
   for opioid use disorder, 905
Basal insulin, 655–656
Bazedoxetine, for osteoporosis, 812–816
Beclabuvir, for hepatitis C, 827–834
Benazepril, 672
Benign prostatic hyperplasia, 800–803
Benzodiazepines
   for back pain, 876
   for opioid use disorder, 905
Beta blockers
   for essential tremors, 741, 745–746
   interactions with, 945
Beta-adrenergic blockers, for hypertension, 676–677
Beta2-agonists, for asthma, 859, 862
Betamethasone, for osteoarthritis, 882–883
Betaxolol, 676
Biologic agents, for asthma, 863–864
Biologic disease-modifying antirheumatic medications, 727–728
Bisacodyl, for irritable bowel syndrome, 836
Bismuth subsalicylate, 841–842
Bisoprolol, 676
Bisphosphonates, for osteoporosis, 811–815, 820–821
Blood pressure, elevated. See Hypertension.
Bone loss. See Osteoporosis.
Bone turnover markers, 819
Botulinum toxin, for drooling, 739, 744
BRIDGE trial, 703
Bulking agents, for irritable bowel syndrome, 835–837
Bumetanide, 670
Bupivacaine, for osteoarthritis, 883
Buprenorphine, for opioid use disorder, 903
Bupropion, for tobacco use disorder, 893–895

C
C1 inhibitor concentrate, for angioedema, 860–861
Calcineurin inhibitors, 727
Calcitonin, 818, 879
Calcium channel blockers
  for hypertension, 674–675
  interactions with, 945
Calcium supplementation, for osteoporosis, 811
Canagliflozin, 652, 654, 686
Cancer-associated venous thromboembolism, 701
Candesartan, 673
CANVAS trials, 918–919
Capsaicin
  for neuropathic pain, 880–881
  for osteoarthritis, 881
Captopril, 672
Carbamazepine, for restless leg syndrome, 751, 753
Carbidopa, for Parkinson’s disease, 736, 742, 744
Carbidopa/levodopa
  for Parkinson’s disease, 734–735, 742
  for restless leg syndrome, 753
Carisoprodol, for back pain, 875–876
Carvedilol, 677
Catechol O-methyltransferase inhibitors, for Parkinson’s disease, 738
Ceftaroline, as novel agent, 918–919
Ceftazidime-avibactam, as novel agent, 921–922
Ceftolozane-tazobactam, as novel agent, 919–921
Celecoxib, for musculoskeletal pain, 871–872
Certolizumab, 728
Cetirizine, 857
CHADS score, 697–698
CHARM-Added trial, 684
Chlorthalidone, 670
Chocolate, for hypertension, 687
Chondroitin, for osteoarthritis, 881–882
Cigarette smoking, 893–896
Cimetidine, 839–843
Citalopram, for vasomotor symptoms, 782
Clarithromycin, 841–842
Clinical Institute Withdrawal Assessment for Alcohol, 896
Clonazepam
for Parkinson’s disease, 741, 745
for periodic limb movements of sleep, 754
for restless leg syndrome, 749, 753
Clonidine, 678
  for opioid use disorder, 905
  for restless leg syndrome, 751–753
  for vasomotor symptoms, 782
Clozapine, for Parkinson’s disease, 744
Coagulation, mechanism of, 695–696
Cobicistat, for HIV infection prevention, 931–932, 935, 944–946
Codeine
  for musculoskeletal pain, 874
  use disorder of, 900–905
Colchicine, 721–722
Combination therapy
  for alcohol use disorder, 899
  for contraception, 772–776
  for HIV infection prevention, 927–950
  for hypertension, 680–681, 683–684
  for musculoskeletal pain, 874
  for tobacco use disorder, 895
Constipation
  in irritable bowel syndrome, 835–836
  in Parkinson’s disease, 740, 744
Contraception, 766–778
  combined, 772–776
  during menopause transition, 784
  effectiveness of, 766–767
  emergency, 776–778
  interactions with, 943
  long-acting reversible, 766, 768
  progestin-only, 772
Controller medications, for asthma, 863–864
Corticosteroids, 720–721
  for asthma, 862–864
  for back pain, 877
  for osteoarthritis, 882–883
  for rhinitis, 853–855
  for tendinopathy, 884
  for urticaria, 857
  interactions with, 942, 945
  osteoporosis due to, 819–821
Coumarins. See Vitamin K antagonists.
Cyclobenzaprine, for back pain, 875–876
Cyclosporine, 727

D
Dabigatran, 702, 704–705, 710
Daclatasvir, for hepatitis C, 827–834
Dalbavancin, as novel agent, 915–918
Dalteparin, 701
Danaparoid, 712–714
Danazol, for angioedema, 861
Danoprevir, for hepatitis C, 827–834
Dantrolene, for back pain, 875–876
Dapaglitiflozin, 652, 654, 686
Darifenacin, for benign prostatic hyperplasia, 802
Darunavir, for HIV infection prevention, 931–932, 941
Dasabuvir, for hepatitis C, 827–834
D-dimer measurement, 698
Decongestants, for rhinitis, 854–855
Dementia, in Parkinson’s disease, 740
Denosumab, for osteoporosis, 812–815, 817–818
Depot-medroxyprogesterone acetate, 772
Depression, in Parkinson’s disease, 740, 745
Desipramine, 877–878
Desvenlafaxine, for vasomotor symptoms, 782
Detoxification
   for alcohol use disorder, 896
   for opioid use disorder, 900
Dexamethasone, for osteoarthritis, 882–883
Dexlansoprazole, 838–843
Diabetes mellitus, hypertension with, 668–669
Diabetes type 2, therapy for, 647–663
   benefits of, 648–649
   in elderly persons, 658
   in macrovascular complications, 658–659
   in renal dysfunction, 657–658
   injectable agents, 654–657
   oral agents, 649–654
Diarrhea, in irritable bowel syndrome, 836–837
Diazepam, for back pain, 876
Diclofenac, for musculoskeletal pain, 871–872
Digoxin, interactions with, 945
Dihydropyridines, 674
Diltiazem, 675
Dipeptidyl-peptidase 4 inhibitors, 651–653, 657
Direct oral anticoagulants, 710–712
   clinical applications of, 697–703
   history of, 696–697
   practical recommendations for, 703–705
Direct-acting antiviral agents, for hepatitis C, 827–834
DISCOVER trials, 916–917
Disease-modifying antirheumatic medications, 724–729
Disulfiram, for alcohol use disorder, 897–898
Diuretics, 670–671
DMARDs (disease-modifying antirheumatic medications), 724–729
Dolutegavir, for HIV infection prevention, 931–932, 941–944
Dopamine agonists
   for Parkinson’s disease, 736–737, 742
   for restless leg syndrome, 749–751
Doxazosin, 678, 801
Drinking problems, 896–900
Drooling, in Parkinson’s disease, 739, 744
Droxidopa, for orthostatic hypotension, 740
Drug abuse. See Substance abuse disorders.
Dual-energy x-ray absorptiometry, for osteoporosis, 808–809
Dulaglutide, 654–655
Duloxetine, 877–879
Dutasteride, for benign prostatic hyperplasia, 802

E
ecallantide, for angioedema, 860
Edoxaban, 699–700, 702, 711
Efavirenz, for HIV infection prevention, 931–932, 940, 943
Elbavir, for hepatitis C, 827–834
Elderly persons. See Older adults.
Electrostimulation therapy, for hypertension, 688
Eluxadoline, for irritable bowel syndrome, 835–837
Elvitegravir, for HIV infection prevention, 931–932, 935, 941–945
Emergency contraception, 776–778
Empaglitiflozin, 652, 654, 686
Emtricitabine, for HIV infection prevention, 931–932, 935–936, 938
Enalapril, 672
Enfuvirtide, for HIV infection prevention, 931
Enoxaparin, 701
Entacapone, for Parkinson’s disease, 743
Entry inhibitors, for HIV prevention, 929–946
Environmental controls, for rhinitis, 856
Eplerenone, 671
Eprosartan, 673
Epsilon-aminocaproic acid, for angioedema, 861
Erectile dysfunction, 797–800
Escitalopram, for vasomotor symptoms, 782
Esomeprazole, 838–843
Estrogens
  for osteoporosis, 812–815, 818
  in contraceptives, 772–776
  in menopause, 778–781
  uses of, 764–766, 769–771
Etanercept, 728
Ethacrynic acid, 670
Ethanol use disorder, 896–900
Etodolac, for musculoskeletal pain, 871–872
Etonorgesterel, interactions with, 943
Etravirine, for HIV infection prevention, 931, 940, 944
Exenatide, 654–655

F
Famotidine, 839–843
Febuxostat, 723
Felodipine, 674
Females, sexual health of. See Women’s health.
FEM-PrEP study, 937–938
Fentanyl
  for musculoskeletal pain, 874
  interactions with, 946
Fesoterodine, for benign prostatic hyperplasia, 802
Fetal alcohol disorders, 899
Fiber, for irritable bowel syndrome, 835–837
Finasteride, for benign prostatic hyperplasia, 802
Fludrocortisone, for orthostatic hypotension, 740, 744
Fluoxetine, for vasomotor symptoms, 782
FOCUS trials, 919
Fondaparinux, 702, 712–714
Fosinopril, 672
Fractures
  in osteoporosis. See Osteoporosis.
  vertebral compression, 877, 879
FRAX calculator, for osteoporosis, 808, 810
Fresh frozen plasma, for angioedema, 860
Furosemide, 670

G

Gabapentin
  for alcohol use disorder, 899
  for essential tremors, 747
  for neuropathic pain, 880
  for restless leg syndrome, 751, 753
  for vasomotor symptoms, 782
Gastrointestinal diseases, 817–850
  gastroesophageal reflux disease, 838–843
  hepatitis C, 827–834
  irritable bowel syndrome, 834–838
  peptic ulcer disease, 838–843
Genitourinary syndrome of menopause, 781–784
Giant cell arteritis, 720
Glimipiride, 650–651
Glipizide, 650–651, 657
Glucagon-like peptide-1 receptor agonists, 654–655
Glucosamine, for osteoarthritis, 881–882
Glucose control, in type 2 diabetes. See Diabetes type 2.
Glyburide, 650–651
Glyceryl trinitrate, for tendinopathy, 884
Glycopyrrolate, for drooling, 739, 744
Golimumab, 728
Gout, 685, 720–724
Grazoprevir, for hepatitis C, 827–834
GS-9857, for hepatitis C, 827–834
Guanfacine, 678
Hallucinations, in Parkinson’s disease, 740, 744
Health Outcomes and reduced Incidence with Zoledronic acid Once Yearly (HORIZON)
   Pivotal fracture trial, 814
Heart failure, hypertension with, 669
Heartburn, therapy for, 838–843
**Helicobacter pylori** infections, 841–842
Hemodialysis, restless leg syndrome in, 752, 754
Heparins, 698, 701–704, 712–714
Hepatitis C, 827–834
Herbal therapies, for benign prostatic hyperplasia, 802
Hereditary angioedema, 858–859
Heroin use disorder, 900–905
Hirudins, 712–714
Histamine receptor antagonists, 839–843, 942
Hives (urticaria), 856–858
HORIZON (Health Outcomes and reduced Incidence with Zoledronic acid Once Yearly)
   Pivotal fracture trial, 814
Hormones. See Men’s health; Women’s health; specific hormones.
Hot flashes, in menopause, 778–781
Human immunodeficiency virus infection
   hepatitis C with, 833–834
   prevention of, 927–950
Hyaluronic acid, for osteoarthritis, 883
Hydralazine, 679
Hydrochlorothiazide, 670
Hydrocodone, for musculoskeletal pain, 874
Hydromorphone, for musculoskeletal pain, 874
Hydroxychloroquine, 726
Hyperglycemia, reduction of, in type 2 diabetes. See Diabetes type 2.
Hypertension, therapy for, 665–693
   combination, 683–684
   diabetes type 2 with, 658
   diabetes with, 668–669
   gout with, 685
   initial agent, 668–669
   lifestyle modifications, 686
   new drugs, 686
   nonpharmacologic, 687
   procedural approaches, 688
   second agent addition, 669, 681–682
   spironolactone addition, 684–685
   targets for, 665–668
   timing of, 682
Hypogonadism, male, 792–797

I
Ibandronate, for osteoporosis, 811–815
Ibuprofen, for musculoskeletal pain, 871–872
Icatibant, for angioedema, 860
Immunosuppressive therapy, 719–731
Immunotherapy, for rhinitis, 856
Impotence (erectile dysfunction), 797–800
Indapamide, 670
Indomethacin, for musculoskeletal pain, 871–872
Infliximab, 728
Inhaled corticosteroids, for asthma, 862–864
INSIGHT-START group, for HIV prevention study, 929
Insulin, 655–657
Integrase inhibitors, for HIV prevention, 929–946
Intraabdominal infections, short-course antimicrobial therapy for, 914
Intrauterine devices, 766, 768–772
Ipratropium, for drooling, 739
iPREX study, 938
Irbesartan, 673
Iron deficiency, in restless leg syndrome, 752
Irritable bowel syndrome, 834–838
Isradipine, 674

K
Ketorolac, for musculoskeletal pain, 871–872
Kidney dysfunction
  diabetes type 2 with, 657–658
  hypertension with, 669
  restless leg syndrome with, 752, 754

L
Labetalol, 677
Lamivudine, for HIV infection prevention, 931–932, 940
Lansoprazole, 838–843
Laxatives, for irritable bowel syndrome, 835–837
Ledipasvir, for hepatitis C, 827–834
Leflunomide, 726–727
Legs, restless, 741, 746–748
Leukotriene blockers
  for asthma, 863–864
  for rhinitis, 853, 856
Levodopa
  for Parkinson’s disease, 734–735
  for restless leg syndrome, 749
Levonorgestrel, 776–778, 943
Lidocaine
  for neuropathic pain, 880
  for osteoarthritis, 881, 883
Lifestyle modifications, for hypertension, 686
Linaclotide, for irritable bowel syndrome, 835–837
Linagliptin, 651–652
Liraglutide, 654–655
Lisinopril, 672
Long-acting beta agonists, for asthma, 863–864
Long-acting reversible contraception, 766, 768–772
Loop diuretics, 670–671
Loperamide
  for irritable bowel syndrome, 835–837
  for opioid use disorder, 905
Losartan, 673, 724
Lubiprostone, for irritable bowel syndrome, 835–837
Lung involvement. See Pulmonology and allergy.

M

Macrovascular complications, in diabetes type 2, 658–659
MAGELLAN trial, 702
Males, sexual health of. See Men’s health.
Maravirox, for HIV infection prevention, 931
Massage, for hypertension, 687
Mast cell–mediated angioedema, 859
Melatonin, for Parkinson’s disease, 741, 745
Meloxicam, for musculoskeletal pain, 871–872
Menopause, 778–784
  osteoporosis after. See Osteoporosis.
Men’s health, 791–805
  benign prostatic hyperplasia, 800–803
  erectile dysfunction, 797–800
  hypogonadism, 792–797
  osteoporosis, 821–822
Mepolizumab, for asthma, 863–864
Mericitavine, for hepatitis C, 827–834
Metaxalone, for back pain, 875–876
Metformin, 649–650, 653, 943
Methadone
  for opioid use disorder, 902, 905
  interactions with, 942
Methocarbamol, for back pain, 875–876
Methotrexate, 725–726
Methylprednisolone
  for back pain, 877
  for neck pain, 874
  for osteoarthritis, 882–883
Metolazone, 670
Metoprolol, 676
Metronidazole, 841–842
Midodrine, for orthostatic hypotension, 740, 744
Minoxidil, 679
Misoprostol, 843
Moexipril, 672
Monoamine oxidase inhibitors, for Parkinson’s disease, 737–738
Montelukast, 856
Morphine, for musculoskeletal pain, 874
Morphine use disorder, 900–905
Mother-to-child transmission, of HIV, prevention of, 934
Movement disorders, 733–761
   essential tremors, 741, 746–748
   Parkinson’s disease, 733–745
   restless leg syndrome, 748–754
Muscle relaxants, for back pain, 875–876
Musculoskeletal conditions, 869–890
   acute pain, 870–874
   neck and back pain, 874–877
   neuropathic pain, 879–881
   osteoarthritis, 881–883
   tendinopathy, 884
   vertebral compression fractures, 877, 879
Mycophenolate, 727

N
Nabumetone, for musculoskeletal pain, 871–872
Nadolol, 676, 746
Naltrexone
   for alcohol use disorder, 896–897
   for opioid use disorder, 904
Naproxen, for musculoskeletal pain, 871–872
Nasal symptoms, in rhinitis, 852–856
National Action Plan for Combating Antimicrobial-Resistant Bacteria, 912
Nausea, in Parkinson’s disease, 744
Nebivolol, 677
Neck pain, 874–877
NEPHRON-D trial, 684
Neuropathic pain, 879–881
Nicardipine, 674
Nicotine addiction, 893–896
Nicotine replacement therapy, 893
Nifedipine, 674
Night sweats, in menopause, 778–781
Nisoldipine, 674
Nizatidine, 839–843
Nondihydropyridines, 675
Nonmotor symptoms, in Parkinson’s disease, 739–741, 744–745
Non-nucleoside reverse transcriptase inhibitors, for HIV prevention, 929–946
Nonsteroidal anti-inflammatory drugs, 719–720
   for musculoskeletal pain, 870–872
   for opioid use disorder, 905
   for osteoarthritis, 881
   for tendinopathy, 884
   ulcers due to, 843
Norepinephrine receptor reuptake inhibitors, 877–879
Nortriptyline, 877–878, 893–895
Nucleoside reverse transcriptase inhibitors, for HIV prevention, 929–946
Occupational exposure, to HIV, prevention of, 934–937
Octreotide, for opioid use disorder, 905
Older adults
  alcohol use disorder in, 900
  diabetes type 2 in, 658
  opioid use disorder in, 905
  tobacco use disorder in, 896
Olmesartan, 673
Omalizumab
  for asthma, 863–864
  for urticaria, 858
Ombitasvir, for hepatitis C, 827–834
Omeprazole, 838–843
Ondansetron, for irritable bowel syndrome, 835–837
ONTARGET trial, 684
Opioid(s)
  for back pain, 875
  for musculoskeletal pain, 873–874
  for osteoarthritis, 881
  for restless leg syndrome, 752
  pharmacology of, 900
  withdrawal from, 904–905
Opioid use disorder, 900–905
Oritavancin, as novel agent, 915–918
Orthopedic surgery, anticoagulants for, 702
Orthostatic hypotension, in Parkinson’s disease, 740, 744
Osteoarthritis, 881–883
Osteoporosis, 807–826
  definition of, 809–810
  diagnosis of, 809–810
  glucocorticoid-induced, 819–821
  risk factors for, 808
  screening for, 808–809
  treatment of, 810–822
    vertebral compression fractures in, 877, 879
Oxybutynin, for benign prostatic hyperplasia, 802
Oxycodone
  for musculoskeletal pain, 874
  use disorder of, 900–905
Oxymetazoline, for rhinitis, 856

Padua Prediction Score, 702
Pain, musculoskeletal
  acute, 870–874
  neck and back, 874–877
  neuropathic, 879–881
Pantoprazole, 838–843
Parenteral anticoagulants, 712–714
Paritaprevir, for hepatitis C, 827–834
Parkinson’s disease, 733–745
Paroxetine, for vasomotor symptoms, 782
PARTNER study, 928
Patches, contraceptive, 772–776
Pegloticase, 724
Penbutolol, 677
Peptic ulcer disease, 838–843
Perindopril, 672
Periodic limb movements of sleep, 754
Peripheral neuropathy, restless leg syndrome in, 754
Pharmacologic therapies
  anticoagulants, 695–718
  antimicrobial agents for. See Antimicrobial agents.
  for allergy, 851–868
  for autoimmune conditions, 719–731
  for diabetes type 2, 647–663
  for gastrointestinal diseases, 827–850
  for HIV infection prevention, 927–950
  for hypertension, 665–693
  for infections. See Antimicrobial agents.
  for men’s health, 791–805
  for movement disorders, 733–761
  for musculoskeletal conditions, 869–890
  for osteoporosis, 807–826
  for pulmonology, 851–868
  for rheumatic conditions, 719–731
  for substance abuse disorders, 892–910
  for women’s health, 763–789
Phenprocoumon. See Vitamin K antagonists.
Phenylephrine, for rhinitis, 856
Phosphodiesterase inhibitors, 798–799
  for benign prostatic hyperplasia, 802
  interactions with, 946
Pills, contraceptive, 772–776
Pindolol, 677
Pioglitazone, 652
Piroxicam, for musculoskeletal pain, 871–872
Polyethylene glycol, for irritable bowel syndrome, 836
Polymyalgia rheumatica, 720–721
Potassium-sparing diuretics, 671
Pramipexole
  for Parkinson’s disease, 736, 742
  for restless leg syndrome, 749, 751
Prandial insulin, 656–657
Prazosin, 678
Prednisone, 720, 877–878
Pregabalin
  for neuropathic pain, 880
  for restless leg syndrome, 751, 753
Pregnancy
  alcohol use disorder in, 899
  opioid use disorder in, 905
  restless leg syndrome in, 752
  tobacco use disorder in, 895–896
Prescription behavior, concordant with guidelines, 914–915
Primidone, for essential tremors, 746–747
Probenecid, 723–724
Probiotics, for irritable bowel syndrome, 835–837
Progestin contraceptives, 768–778
Progestin-only pill, 772
Progestogens, uses of, 764–766
Promethazine, for opioid use disorder, 905
Propranolol, 676, 741, 746
Prostate, benign hyperplasia of, 800–803
Protease inhibitors, for HIV prevention, 929–946
Proton pump inhibitors, 838–842, 942
Pseudoephedrine, for rhinitis, 856
Pseudogout, 721
Psychosis, in Parkinson’s disease, 740
Psyllium, for irritable bowel syndrome, 835–837
Pulmonary embolism, anticoagulants for, 698
Pulmonology and allergy, therapies in, 851–868
  for angioedema, 858–859
  for asthma, 859–865
  for rhinitis, 852–856
  for urticaria, 856–858
Q
Quetiapine, for Parkinson’s disease, 744
Quinapril, 672
R
Rabeprazole, 838–843
Radiofrequency therapy, for hypertension, 688
Raloxifene, for osteoporosis, 812–816
Raltegravir, for HIV infection prevention, 931–932, 941
Ramipril, 672
Ranitidine, 839–843
Rapid eye movement sleep behavior disorder, 741, 745
Rasagiline, for Parkinson’s disease, 738, 742
Renin-angiotensin system inhibitors, for hypertension, 672–673
Resistance, to antibiotics, guidelines for, 912–915
Respiratory system. See Pulmonology and allergy.
Restless leg syndrome, 741, 746–754
Rheumatoid arthritis, 720–721
Rheumatologic conditions, therapy for, 719–731
Rhinitis, 852–856
Ribavirin, for hepatitis C, 827–834
Rifaximin, for irritable bowel syndrome, 835–837
Rilpivirine, for HIV infection prevention, 931–946
Rings, contraceptive, 772–776
Risedronate, for osteoporosis, 811–815
Ritonavir
  for hepatitis C, 827–834
  for HIV infection prevention, 931, 942–946
Rituximab, 728
Rivaroxaban, 699–700, 702, 710–711
Rivastigmine, for dementia, 740
Ropinirole
  for Parkinson’s disease, 736, 742
  for restless leg syndrome, 749, 751, 753
Ropivacaine, for osteoarthritis, 883
Rosiglitazone, 652
Rosuvastatin, for diabetes type 2, 659
Rotigotine, for Parkinson’s disease, 736–737, 742

S
Salmeterol Multicenter Asthma study Research Trial (SMART), 863–864
Samatasvir, for hepatitis C, 827–834
Saxagliptin, 651–652
Selective estrogen receptor modulators
  for osteoporosis, 812–816
  uses of, 764–766
Selective progesterone receptor modulators, uses of, 764–766
Selective serotonin receptor uptake inhibitors, 837
Seligline, for Parkinson’s disease, 737, 742
Senna, for irritable bowel syndrome, 836
Sildenafil, 798–799
Silodosin, for benign prostatic hyperplasia, 801
Simeprevir, for hepatitis C, 827–834
Sitagliptin, 651–652
Sleep, periodic limb movements of, 754
SMART (Salmeterol Multicenter Asthma study Research Trial), 863–864
Smoking, 893–896
Sodium picosulfate, for irritable bowel syndrome, 836
Sodium-glucose cotransporter 2 inhibitors, 652–654, 686
Sofosbuvir, for hepatitis C, 827–834
Solifenacin, for benign prostatic hyperplasia, 802
SOLO trials, 917
Sotalol, for essential tremors, 746
Spasticity, 875–876
Spironolactone, 671, 684–685
SPRINT (Systolic Blood Pressure Intervention Trial), 666–668
Staphylococcus aureus, methicillin-resistant, antimicrobials for, 912–914
Statins
  for diabetes type 2, 658–659
  interactions with, 942
<table>
<thead>
<tr>
<th>Page Range</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>913–914</td>
<td>STOP MRSA (Strategies Using Off-Patent Antibiotics for Methicillin-Resistant Staphylococcus aureus)</td>
</tr>
<tr>
<td>697–698</td>
<td>Stroke, in atrial fibrillation</td>
</tr>
<tr>
<td>818–819</td>
<td>Strontium ranelate, for osteoporosis</td>
</tr>
<tr>
<td>766, 768–772</td>
<td>Subdermal protein implants</td>
</tr>
<tr>
<td>891–910</td>
<td>Substance use disorders</td>
</tr>
<tr>
<td>896–900</td>
<td>alcohol use</td>
</tr>
<tr>
<td>892</td>
<td>diagnosis of</td>
</tr>
<tr>
<td>900–905</td>
<td>opioid use</td>
</tr>
<tr>
<td>891–892</td>
<td>screening for</td>
</tr>
<tr>
<td>893–896</td>
<td>tobacco use</td>
</tr>
<tr>
<td>892–893</td>
<td>treatment of</td>
</tr>
<tr>
<td>726</td>
<td>Sulfasalazine</td>
</tr>
<tr>
<td>650–651, 653</td>
<td>Sulfonylureas</td>
</tr>
<tr>
<td>871–872</td>
<td>Sulindac, for musculoskeletal pain</td>
</tr>
<tr>
<td>702–703</td>
<td>Surgery, anticoagulants for</td>
</tr>
<tr>
<td>827–828</td>
<td>Sustained virologic response, in hepatitis C treatment</td>
</tr>
<tr>
<td>688</td>
<td>SYMPLICITY-HTN trial</td>
</tr>
<tr>
<td>720–721</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>666–668</td>
<td>Systolic Blood Pressure Intervention Trial (SPRINT)</td>
</tr>
<tr>
<td>727</td>
<td>Tacrolimus</td>
</tr>
<tr>
<td>798–799, 802</td>
<td>Tadalafil</td>
</tr>
<tr>
<td>687</td>
<td>Tai chi, for hypertension</td>
</tr>
<tr>
<td>801</td>
<td>Tamulosin, for benign prostatic hyperplasia</td>
</tr>
<tr>
<td>938</td>
<td>TDF-2 study</td>
</tr>
<tr>
<td>687</td>
<td>Tea, for hypertension</td>
</tr>
<tr>
<td>673</td>
<td>Telmisartan</td>
</tr>
<tr>
<td>884</td>
<td>Tendinopathy</td>
</tr>
<tr>
<td>931–946</td>
<td>Tenofovir, for HIV infection prevention</td>
</tr>
<tr>
<td>678, 801</td>
<td>Terazosin</td>
</tr>
<tr>
<td>810–817</td>
<td>Teriparatide</td>
</tr>
<tr>
<td>792–797</td>
<td>Testosterone, for hypogonadism</td>
</tr>
<tr>
<td>821–822</td>
<td>for osteoporosis</td>
</tr>
<tr>
<td>841–842</td>
<td>Tetracycline</td>
</tr>
<tr>
<td>670</td>
<td>Thiazide diuretics</td>
</tr>
<tr>
<td>652–654</td>
<td>Thiazolidinediones</td>
</tr>
<tr>
<td>728</td>
<td>Tocilizumab</td>
</tr>
<tr>
<td>738, 743</td>
<td>Tolcapone, for Parkinson’s disease</td>
</tr>
<tr>
<td>899</td>
<td>Topiramate, for alcohol use disorder</td>
</tr>
<tr>
<td>747–748</td>
<td>for essential tremors</td>
</tr>
</tbody>
</table>
Torsemide, 670
Tramadol
    for musculoskeletal pain, 873
    for neuropathic pain, 879
    for osteoarthritis, 881
Trandolapril, 672
Tranexamic acid, for angioedema, 861
Trazodone, for erectile dysfunction, 798–799
Tremors, essential, 741, 746–748
Triamcinolone acetonide, for osteoarthritis, 882–883
Tricyclic antidepressants
    for back pain, 877–878
    for irritable bowel syndrome, 837
    for neuropathic pain, 879
Trihexyphenidyl, for Parkinson’s disease, 739
Trimethoprim-sulfamethoxazole, for MRSA infections, 913–914
Trimethylbenzamide, for Parkinson’s disease, 736, 742, 744
Trospium, for benign prostatic hyperplasia, 802
Type 2 diabetes. See Diabetes type 2.

U
U-500 insulin, 657
UKPDS (UK Prospective Diabetes Study), 648
Ulcers, peptic, 838–843
Ulipristal, 777–778
Urate-lowering therapy, 722
Urinary tract infections, antibiotic trials for, 919–921
Urticaria, 856–858
Usteikinumab, 728

V
Vaccinations, with antirheumatic drug therapy, 729
Vacuum pumps, for erectile dysfunction, 800
VADT (Veterans Affairs Diabetes Trial), 648
Vaginal rings, contraceptive, 772–776
Valsartan, 673
Valsartan Heart Failure Trial, 683–684
Vardenafil, 798–799
Varenicline, for tobacco use disorder, 893–895
Vasculitis, 720
Vasodilators, for hypertension, 679
Vasomotor symptoms, in menopause, 778–781
Vedoprevir, for hepatitis C, 827–834
Venlafaxine, 782, 877–878
Venous thromboembolism, anticoagulants for. See Anticoagulants.
Verapamil, 675, 748
Vertebral compression fractures, 877, 879
Veterans Affairs Diabetes Trial (VADT), 648
Vitamin D, for osteoporosis, 811
Vitamin K antagonists, 705–710
   clinical applications of, 697–698
   history of, 696
   practical recommendations for, 703–705
Vivalirudin, 712–714
VOICE study, 937–938

W
Warfarin, 705–710
   clinical applications of, 697–698
   history of, 696
   practical recommendation for, 703–705
Weight reduction, for hypertension, 686
White House stewardship initiative, for antibiotic use, 912
Withdrawal, in alcohol use disorder, 896
Women’s health, 763–789
   contraception, 766–778
   hormone therapy for, contraindications to, 769–771
   menopause, 778–784

Y
Yohimbine, for erectile dysfunction, 798
Yolterone, for benign prostatic hyperplasia, 802
Yuzpe method, 776–778

Z
Zafirlukast, 856
Zidovudine, for HIV infection prevention, 931–932, 934, 940
Zileuton, 856, 864
Zoledronate, for osteoporosis, 812–815